Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluation of Allied Healthcare in Patients Recovering From COVID-19 (ParaCOV)

9. mai 2022 oppdatert av: Radboud University Medical Center

SUMMARY Rationale: Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) might play an important role in the recovery of patients with COVID-19 who experience limitations in daily physical functioning and participation. However, the evidence base for allied healthcare in patients with COVID-19 has yet to be established. To facilitate care for people recovering from COVID-19 and to establish this evidence base, the Dutch ministry has created a temporary regulation for primary care allied healthcare specifically for patients with COVID-19.

Objective: This study is setup alongside the temporary regulation and aims to evaluate the longitudinal recovery trajectories and related costs of patients who visited a primary care allied healthcare professional for the management of severe symptoms and activity limitations and/or participation restrictions related to COVID-19.

Study design: Prospective cohort study. Study population: 1,315 adult patients recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease will be eligible for this study.

Intervention (if applicable): Although the nature of this study is non-experimental, the allied healthcare intervention can be considered experimental due to the novelty of the disease.

Main study parameters/endpoints: The primary outcome domain of this study is participation measured with the Utrechtse Schaal voor Revalidatie - Participatie (USER-P). The primary endpoint is set at 6 months. A 5 point difference will be considered clinically relevant for patients with COVID-19.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There are no specific risks involved with participation in this study, as it entails the completion of questionnaires over the timeframe of one year (at the start of the treatment, the end of the treatment, 3 months, 6 months, 9 months and 12 months). The load of the survey will be highest at months 3, 6 and 12 with a total of 74 survey items. Input from patient representatives suggested that this number of items was feasible, especially because participants are allowed to complete the survey over a number of days. Finally, none of the items in the survey are considered emotionally distressing. The prescribed interventions are conform the recommendations of the best available evidence and are in line with usual allied healthcare interventions. Therefore, risks are likely to be negligible conform usual allied healthcare.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Faktiske)

1441

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Gelderland
      • Nijmegen, Gelderland, Nederland, 6500HB
        • Radboud University Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

N/A

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Adult patients of 18 year and older recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, who are referred to a primary care allied health professional* by a general practitioner or medical specialist are deemed eligible for this study.

*Allied health professionals relevant to this study are: Dietitians, Exercise Therapists, Occupational Therapists, Physical Therapists, and Speech and Language Therapists working in primary care in the Netherlands.

Beskrivelse

Inclusion Criteria:

Adult patients

  • recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and;
  • who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease; will be eligible for this study. The need for referring the patient to an allied health professional will be judged by the primary care physician or medical specialist. Criteria for referral are described in guidance published by the Long Alliantie Nederland (LAN) with recommendations for treatment of post-COVID-19-patients: the COVID-19 Associated Syndrome (CAS) (Chapters 3.3 and 4).

http://www.longalliantie.nl/files/2515/9359/4621/Handreiking_voor_de_zorg.pdf

Exclusion Criteria:

Adult patients:

- receiving palliative care; are excluded from this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Prospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
Retrospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participation
Tidsramme: Baseline (T0)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
Baseline (T0)
Participation
Tidsramme: 3 months (T1)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
3 months (T1)
Participation
Tidsramme: 6 months (T2)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
6 months (T2)
Participation
Tidsramme: 12 months (T3)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
12 months (T3)
Quality of life measured with EQ-5D-5L
Tidsramme: Baseline (T0)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
Baseline (T0)
Quality of life measured with EQ-5D-5L
Tidsramme: 3 months (T1)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
3 months (T1)
Quality of life measured with EQ-5D-5L
Tidsramme: 6 months (T2)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
6 months (T2)
Quality of life measured with EQ-5D-5L
Tidsramme: 12 months (T3)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
12 months (T3)
Fatigue
Tidsramme: Baseline (T0)
Measured with the Fatigue Severity Scale (FSS)
Baseline (T0)
Fatigue
Tidsramme: 3 months (T1)
Measured with the Fatigue Severity Scale (FSS)
3 months (T1)
Fatigue
Tidsramme: 6 months (T2)
Measured with the Fatigue Severity Scale (FSS)
6 months (T2)
Fatigue
Tidsramme: 12 months (T3)
Measured with the Fatigue Severity Scale (FSS)
12 months (T3)
Physical functioning
Tidsramme: Baseline (T0)
PROMIS Physical Functioning Short Form 10b (10 items).
Baseline (T0)
Physical functioning
Tidsramme: 3 months (T1)
PROMIS Physical Functioning Short Form 10b (10 items).
3 months (T1)
Physical functioning
Tidsramme: 6 months (T2)
PROMIS Physical Functioning Short Form 10b (10 items).
6 months (T2)
Physical functioning
Tidsramme: 12 months (T3)
PROMIS Physical Functioning Short Form 10b (10 items).
12 months (T3)
Costs
Tidsramme: Baseline (T0)
will be measured using a cost questionnaire (18 items)
Baseline (T0)
Costs
Tidsramme: 3 months (T1)
will be measured using a cost questionnaire (18 items)
3 months (T1)
Costs
Tidsramme: 6 months (T2)
will be measured using a cost questionnaire (18 items)
6 months (T2)
Costs
Tidsramme: 9 months (T3)
will be measured using a cost questionnaire (18 items)
9 months (T3)
Costs
Tidsramme: 12 months (T4)
will be measured using a cost questionnaire (18 items)
12 months (T4)
Patient Specific Activities
Tidsramme: baseline (T0) as part of usual care
measured with the Patient Specific Complaints (PSC)
baseline (T0) as part of usual care
Patient Specific Activities
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the Patient Specific Complaints (PSC)
end of the treatment as part of usual care (average of 6 months)
Nutritional Status
Tidsramme: baseline (T0) as part of usual care
measured with the BMI (weight and height)
baseline (T0) as part of usual care
Nutritional Status
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the BMI (weight and height)
end of the treatment as part of usual care (average of 6 months)
Global Assessment
Tidsramme: baseline (T0) as part of usual care
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
baseline (T0) as part of usual care
Global Assessment
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
end of the treatment as part of usual care (average of 6 months)
Voice Problems
Tidsramme: baseline (T0) as part of usual care
measured with Voice Handicap Index (VHI)
baseline (T0) as part of usual care
Voice Problems
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with Voice Handicap Index (VHI)
end of the treatment as part of usual care (average of 6 months)
Swallowing Problems
Tidsramme: baseline (T0) as part of usual care
Dysphagia Handicap Index (DHI).
baseline (T0) as part of usual care
Swallowing Problems
Tidsramme: end of the treatment as part of usual care (average of 6 months)
Dysphagia Handicap Index (DHI).
end of the treatment as part of usual care (average of 6 months)
Patient Specific Activities
Tidsramme: baseline (T0) as part of usual care
measured with the Canadian Occupational Performance Measure (COPM)
baseline (T0) as part of usual care
Patient Specific Activities
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the Canadian Occupational Performance Measure (COPM)
end of the treatment as part of usual care (average of 6 months)
Activities
Tidsramme: baseline (T0) as part of usual care
measured with the PRO-ergo
baseline (T0) as part of usual care
Activities
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the PRO-ergo
end of the treatment as part of usual care (average of 6 months)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Exercise capacity
Tidsramme: baseline (T0) as part of usual care
6 Minute Walk Test (6MWT)
baseline (T0) as part of usual care
Exercise capacity
Tidsramme: end of the treatment as part of usual care (average of 6 months)
6 Minute Walk Test (6MWT)
end of the treatment as part of usual care (average of 6 months)
Exercise capacity
Tidsramme: baseline (T0) as part of usual care
Short Physical Performance Battery (SPPB)
baseline (T0) as part of usual care
Exercise capacity
Tidsramme: end of the treatment as part of usual care (average of 6 months)
Short Physical Performance Battery (SPPB)
end of the treatment as part of usual care (average of 6 months)
Quadriceps strength
Tidsramme: baseline (T0) as part of usual care
with a hand dynamometer.
baseline (T0) as part of usual care
Quadriceps strength
Tidsramme: end of the treatment as part of usual care (average of 6 months)
with a hand dynamometer.
end of the treatment as part of usual care (average of 6 months)
Hand grip strength
Tidsramme: baseline (T0) as part of usual care
with a hand dynamometer.
baseline (T0) as part of usual care
Hand grip strength
Tidsramme: end of the treatment as part of usual care (average of 6 months)
with a hand dynamometer.
end of the treatment as part of usual care (average of 6 months)
Bioimpedance (BIA
Tidsramme: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Bioimpedance (BIA
Tidsramme: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
VAS-appetite, taste and smell
Tidsramme: baseline (T0) as part of usual care
baseline (T0) as part of usual care
VAS-appetite, taste and smell
Tidsramme: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Dietary goal attainment
Tidsramme: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Dietary goal attainment
Tidsramme: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Liquid medical nutrition
Tidsramme: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Liquid medical nutrition
Tidsramme: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Sarcopenia
Tidsramme: baseline (T0) as part of usual care
measured with the SARC-F
baseline (T0) as part of usual care
Sarcopenia
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the SARC-F
end of the treatment as part of usual care (average of 6 months)
Types of Stool
Tidsramme: baseline (T0) as part of usual care
measured with the Bristol Stool Chart (BCS)
baseline (T0) as part of usual care
Types of Stool
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the Bristol Stool Chart (BCS)
end of the treatment as part of usual care (average of 6 months)
Voice Problems
Tidsramme: baseline (T0) as part of usual care
measured with Maximum Phonation Time (MPT)
baseline (T0) as part of usual care
Voice Problems
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with Maximum Phonation Time (MPT)
end of the treatment as part of usual care (average of 6 months)
Swallowing Problems
Tidsramme: baseline (T0) as part of usual care
measured with Maximum Swallowing Speed (MSP)
baseline (T0) as part of usual care
Swallowing Problems
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with Maximum Swallowing Speed (MSP)
end of the treatment as part of usual care (average of 6 months)
Physical Functioning
Tidsramme: baseline (T0) as part of usual care
measured with the Assessment of Motor and Process Skills (AMPS)
baseline (T0) as part of usual care
Physical Functioning
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the Assessment of Motor and Process Skills (AMPS)
end of the treatment as part of usual care (average of 6 months)
Cognitive Functioning
Tidsramme: baseline (T0) as part of usual care
measured with the Cognitive Complaints - Participation (CoCo-P)
baseline (T0) as part of usual care
Cognitive Functioning
Tidsramme: end of the treatment as part of usual care (average of 6 months)
measured with the Cognitive Complaints - Participation (CoCo-P)
end of the treatment as part of usual care (average of 6 months)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Philip van der Wees, Prof. dr., Radboud University Medical Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mars 2021

Primær fullføring (Forventet)

17. juli 2022

Studiet fullført (Forventet)

1. januar 2024

Datoer for studieregistrering

Først innsendt

28. januar 2021

Først innsendt som oppfylte QC-kriteriene

2. februar 2021

Først lagt ut (Faktiske)

3. februar 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. mai 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. mai 2022

Sist bekreftet

1. mai 2022

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere